Show simple item record

dc.contributor.authorMroz, Pawel
dc.contributor.authorYaroslavsky, Anastasia
dc.contributor.authorKharkwal, Gitika B.
dc.contributor.authorHamblin, Michael R.
dc.date.accessioned2014-06-24T14:11:20Z
dc.date.available2014-06-24T14:11:20Z
dc.date.issued2011-06
dc.date.submitted2011-04
dc.identifier.issn2072-6694
dc.identifier.urihttp://hdl.handle.net/1721.1/88087
dc.description.abstractPhotodynamic therapy (PDT) is an emerging cancer therapy that uses the combination of non-toxic dyes or photosensitizers (PS) and harmless visible light to produce reactive oxygen species and destroy tumors. The PS can be localized in various organelles such as mitochondria, lysosomes, endoplasmic reticulum, Golgi apparatus and plasma membranes and this sub-cellular location governs much of the signaling that occurs after PDT. There is an acute stress response that leads to changes in calcium and lipid metabolism and causes the production of cytokines and stress response mediators. Enzymes (particularly protein kinases) are activated and transcription factors are expressed. Many of the cellular responses center on mitochondria and frequently lead to induction of apoptosis by the mitochondrial pathway involving caspase activation and release of cytochrome c. Certain specific proteins (such as Bcl-2) are damaged by PDT-induced oxidation thereby increasing apoptosis, and a build-up of oxidized proteins leads to an ER-stress response that may be increased by proteasome inhibition. Autophagy plays a role in either inhibiting or enhancing cell death after PDT.en_US
dc.description.sponsorshipNational Institutes of Health (U.S.) (NIH grant R01AI050875)en_US
dc.description.sponsorshipCenter for Integration of Medicine and Innovative Technology (DAMD17-02-2-0006)en_US
dc.description.sponsorshipUnited States. Dept. of Defense. Congressionally Directed Medical Research Programs (CDMRP Program in TBI (W81XWH-09-1-0514))en_US
dc.description.sponsorshipUnited States. Air Force Office of Scientific Research (FA9950-04-1-0079)en_US
dc.description.sponsorshipNational Institutes of Health (U.S.) (NIH Dermatology training grant)en_US
dc.language.isoen_US
dc.publisherMDPI AGen_US
dc.relation.isversionofhttp://dx.doi.org/10.3390/cancers3022516en_US
dc.rightsCreative Commons Attributionen_US
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/en_US
dc.sourceMDPI Publishingen_US
dc.titleCell Death Pathways in Photodynamic Therapy of Canceren_US
dc.typeArticleen_US
dc.identifier.citationMroz, Pawel, Anastasia Yaroslavsky, Gitika B Kharkwal, and Michael R. Hamblin. “Cell Death Pathways in Photodynamic Therapy of Cancer.” Cancers 3, no. 4 (June 3, 2011): 2516–2539.en_US
dc.contributor.departmentHarvard University--MIT Division of Health Sciences and Technologyen_US
dc.contributor.mitauthorHamblin, Michael R.en_US
dc.relation.journalCancersen_US
dc.eprint.versionFinal published versionen_US
dc.type.urihttp://purl.org/eprint/type/JournalArticleen_US
eprint.statushttp://purl.org/eprint/status/PeerRevieweden_US
dspace.orderedauthorsMroz, Pawel; Yaroslavsky, Anastasia; Kharkwal, Gitika B; Hamblin, Michael R.en_US
mit.licensePUBLISHER_CCen_US
mit.metadata.statusComplete


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record